FTO and liver cancer: Fto inhibitors like Fb23 and Fb23-2 alter m6A levels of Erbb3 and signaling pathways, suppressing liver cancer cell proliferation and survival173-175, while Dac51 inhibits Fto-mediated glycolysis, showing enhanced efficacy when combined with anti-PD-L1 blockers176.